^
BIOMARKER:

ER positive

i
Other names: ESR1, Era, ESR, NR3A1, ER, ER beta
Entrez ID:
ER positive
Uterine Cancer
anastrozole
Sensitive: C3 – Early Trials
Gynecol Oncol - 2 weeks
ER positive
Uterine Corpus Leiomyosarcoma
anastrozole
Sensitive: C3 – Early Trials
Gynecol Oncol - 2 weeks
ER positive
Estrogen Receptor Positive Breast Cancer
fulvestrant
Sensitive: A1 - Approval
ER positive
Estrogen Receptor Positive Breast Cancer
exemestane
Sensitive: A1 - Approval
ER positive
Estrogen Receptor Positive Breast Cancer
toremifene
Sensitive: A1 - Approval
ER positive
HER2 Positive Breast Cancer
trastuzumab + lapatinib
Sensitive: A2 - Guideline
ER positive
HER2 Negative Breast Cancer
letrozole
Sensitive: A2 - Guideline
ER positive
Uterine Corpus Leiomyosarcoma
Aromatase inhibitor
Sensitive: A2 - Guideline
ER positive
HER2 Negative Breast Cancer
anastrozole
Sensitive: A2 - Guideline
ER positive
Male Breast Cancer
tamoxifen
Sensitive: A2 - Guideline
ER positive
HER2 Positive Breast Cancer
neratinib
Sensitive: A2 - Guideline
ER positive
Uterine Corpus Leiomyosarcoma
medroxyprogesterone
Sensitive: A2 - Guideline
ER positive
Uterine Corpus Leiomyosarcoma
megestrol
Sensitive: A2 - Guideline
ER positive
HER2 Negative Breast Cancer
gimeracil/oteracil/tegafur
Sensitive: B - Late Trials
ER positive
HER2 Negative Breast Cancer
palbociclib
Sensitive: B - Late Trials
ER positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: B - Late Trials
ER positive
HER2 Negative Breast Cancer
GDC-0032
Sensitive: B - Late Trials
ER positive
HER2 Negative Breast Cancer
EC-P
Sensitive: B - Late Trials
ER positive
HER2 Negative Breast Cancer
exemestane
Sensitive: C1 - Off-label
ER positive
HER2 Negative Breast Cancer
fulvestrant
Sensitive: C1 - Off-label
ER positive
Breast Cancer
capecitabine
Sensitive: C2 – Inclusion Criteria
ER positive
Estrogen Receptor Positive Breast Cancer
Z-endoxifen hydrochloride
Sensitive: C2 – Inclusion Criteria
ER positive
Estrogen Receptor Positive Breast Cancer
SAR439859
Sensitive: C2 – Inclusion Criteria
ER positive
Ovarian Cancer
ribociclib
Sensitive: C2 – Inclusion Criteria
ER positive
HER2 Negative Breast Cancer
G1T48
Sensitive: C2 – Inclusion Criteria
ER positive
HER2 Negative Breast Cancer
capecitabine
Sensitive: C2 – Inclusion Criteria
ER positive
HER2 Negative Breast Cancer
TAK-228
Sensitive: C2 – Inclusion Criteria
ER positive
HER2 Negative Breast Cancer
H3B-6545
Sensitive: C2 – Inclusion Criteria
ER positive
Endometrial Cancer
ribociclib + letrozole
Sensitive: C2 – Inclusion Criteria
ER positive
Breast Cancer
trastuzumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
ER positive
HER2 Negative Breast Cancer
ribociclib
Sensitive: C2 – Inclusion Criteria
ER positive
Estrogen Receptor Positive Breast Cancer
alpelisib
Sensitive: C2 – Inclusion Criteria
ER positive
HER2 Negative Breast Cancer
AZD9833
Sensitive: C2 – Inclusion Criteria
ER positive
Estrogen Receptor Positive Breast Cancer
palbociclib
Sensitive: C2 – Inclusion Criteria
ER positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
ER positive
HER2 Negative Breast Cancer
everolimus
Sensitive: C2 – Inclusion Criteria
ER positive
HER2 Negative Breast Cancer
trastuzumab
Sensitive: C2 – Inclusion Criteria
ER positive
HER2 Negative Breast Cancer
palbociclib + PF-05212384
Sensitive: C2 – Inclusion Criteria
ER positive
Breast Cancer
tamoxifen
Sensitive: C2 – Inclusion Criteria
ER positive
HER2 Negative Breast Cancer
palbociclib + GDC-9545
Sensitive: C2 – Inclusion Criteria
ER positive
Estrogen Receptor Positive Breast Cancer
bevacizumab
Sensitive: C3 – Early Trials
ER positive
HER2 Negative Breast Cancer
enobosarm
Sensitive: C3 – Early Trials
ER positive
HER2 Positive Breast Cancer
AC
Sensitive: C3 – Early Trials
ER positive
Endometrial Cancer
palbociclib + letrozole
Sensitive: C3 – Early Trials
ER positive
HER2 Negative Breast Cancer
ZN-c5
Sensitive: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
tamoxifen + TAK-228
Sensitive: C3 – Early Trials
ER positive
HER2 Positive Breast Cancer
lapatinib
Resistant: C3 – Early Trials
ER positive
HER2 Positive Breast Cancer
trastuzumab + palbociclib
Sensitive: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
tamoxifen + GDC-0032
Sensitive: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
venetoclax
Sensitive: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
ribociclib
Sensitive: C3 – Early Trials
ER positive
HER2 Positive Breast Cancer
lapatinib + ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
ER positive
HER2 Negative Breast Cancer
zoledronic acid
Resistant: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
ixazomib
Sensitive: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
ponatinib
Sensitive: C3 – Early Trials
ER positive
HER2 Negative Breast Cancer
ARV-471
Sensitive: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
MLN8237
Sensitive: C3 – Early Trials
ER positive
Hormone Receptor Positive Breast Cancer
ado-trastuzumab emtansine + pertuzumab
Sensitive: C3 – Early Trials
ER positive
HER2 Negative Breast Cancer
LY3484356
Sensitive: C3 – Early Trials
ER positive
HER2 Negative Breast Cancer
venetoclax
Resistant: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
sunitinib
Sensitive: C3 – Early Trials
ER positive
HER2 Negative Breast Cancer
RAD140
Sensitive: C3 – Early Trials
ER positive
Endometrial Adenocarcinoma
letrozole + zoledronic acid
Sensitive: C4 – Case Studies
ER positive
Gastric Cancer
letrozole
Sensitive: C4 – Case Studies
ER positive
Estrogen Receptor Positive Breast Cancer
apalutamide
Sensitive: D – Preclinical
ER positive
Ovarian Cancer
abemaciclib
Sensitive: D – Preclinical
ER positive
HER2 Positive Breast Cancer
doxorubicin hydrochloride
Resistant: D – Preclinical
ER positive
HER2 Positive Breast Cancer
docetaxel
Resistant: D – Preclinical
ER positive
Estrogen Receptor Positive Breast Cancer
RGT-419B
Sensitive: D – Preclinical
ER positive
Endometrial Cancer
abemaciclib + letrozole
Sensitive: D – Preclinical
ER positive
Estrogen Receptor Positive Breast Cancer
MLN4924
Sensitive: D – Preclinical
ER positive
Estrogen Receptor Positive Breast Cancer
palbociclib + CGM097
Sensitive: D – Preclinical
ER positive
Estrogen Receptor Positive Breast Cancer
CGM097
Sensitive: D – Preclinical
ER positive
Estrogen Receptor Positive Breast Cancer
levo-tetrahydropalmatine
Sensitive: D – Preclinical
ER positive
Estrogen Receptor Positive Breast Cancer
MK-2206 + D9
Sensitive: D – Preclinical
ER positive
Estrogen Receptor Positive Breast Cancer
SNG-162
Sensitive: D – Preclinical
ER positive
Estrogen Receptor Positive Breast Cancer
palbociclib + CR-1-31-B
Sensitive: D – Preclinical
ER positive
Estrogen Receptor Positive Breast Cancer
darolutamide
Sensitive: D – Preclinical
ER positive
Estrogen Receptor Positive Breast Cancer
enzalutamide
Sensitive: D – Preclinical
ER positive
Estrogen Receptor Positive Breast Cancer
abemaciclib
Sensitive: D – Preclinical
ER positive
Estrogen Receptor Positive Breast Cancer
palbociclib + ZEN-3694
Sensitive: D – Preclinical
ER positive
Estrogen Receptor Positive Breast Cancer
abemaciclib + ZEN-3694
Sensitive: D – Preclinical
ER positive
Estrogen Receptor Positive Breast Cancer
palbociclib + APG-2575
Sensitive: D – Preclinical
ER positive
Estrogen Receptor Positive Breast Cancer
paclitaxel + eribulin mesylate
Sensitive: D – Preclinical
ER positive
HER2 Negative Breast Cancer
XMT-1660
Sensitive: D – Preclinical
ER positive
Breast Cancer
everolimus + alpelisib + abemaciclib + LY3484356
Sensitive: D – Preclinical
ER positive
Breast Cancer
LY3484356
Sensitive: D – Preclinical
ER positive
HER2 Negative Breast Cancer
Q901
Sensitive: D – Preclinical
ER positive
HER2 Negative Breast Cancer
E7090
Sensitive: D – Preclinical
ER positive
Breast Cancer
SCR6106
Sensitive: D – Preclinical
ER positive
Estrogen Receptor Positive Breast Cancer
sorafenib
Sensitive: D – Preclinical
ER positive
Estrogen Receptor Positive Breast Cancer
metformin
Sensitive: D – Preclinical
ER positive
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: D – Preclinical
ER positive
Breast Cancer
ZEN-3694
Sensitive: D – Preclinical